|
1
|
Furnari FB, Stegh A, Chin L, Fenton T,
Bachoo RM, Hahn WC, et al: Malignant astrocytic glioma: genetics,
biology, and paths to treatment. Genes Dev. 21:2683–2710. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pu P, Xia Z, Yu S and Huang Q: Altered
expression of Cx43 in astrocytic tumors. Clin Neurol Neurosurg.
107:49–54. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sánchez-Alvarez R, Paíno T,
Herrero-González S, Medina JM and Tabernero A: Tolbutamide reduces
glioma cell proliferation by increasing connexin43, which promotes
the up-regulation of p21 and p27 and subsequent changes in
retinoblastoma phosphorylation. Glia. 54:125–134. 2006.
|
|
4
|
Vinken M, Decrock E, De Vuyst E, Ponsaerts
R, D’hondt C, Bultynck G, et al: Connexins: sensors and regulators
of cell cycling. Biochim Biophys Acta. 1815:13–25. 2011.PubMed/NCBI
|
|
5
|
Novakova J, Slaby O, Vyzula R and Michalek
J: MicroRNA involvement in glioblastoma pathogenesis. Biochem
Biophys Res Commun. 386:1–5. 2009. View Article : Google Scholar
|
|
6
|
Liu NK and Xu XM: MicroRNA in central
nervous system trauma and degenerative disorders. Physiol Genomics.
43:571–580. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhou X, Ren Y, Moore L, Mei M, You Y, Xu
P, et al: Downregulation of miR-21 inhibits EGFR pathway and
suppresses the growth of human glioblastoma cells independent of
PTEN status. Lab Invest. 90:144–155. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nan Y, Han L, Zhang A, Wang G, Jia Z, Yang
Y, et al: MiRNA-451 plays a role as tumor suppressor in human
glioma cells. Brain Res. 1359:14–21. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Racagni G, Pezzotta S, Giordana M, Iuliano
E, Mocchetti I, Spanu G, et al: Cyclic nucleotides in experimental
and human brain tumors. J Neurooncol. 1:61–67. 1983.PubMed/NCBI
|
|
10
|
Wakshull E, Hertel C, O’Keefe EJ and
Perkins JP: Cellular redistribution of β-adrenergic receptors in a
human astrocytoma cell line: a comparison with the epidermal growth
factor receptor in murine fibroblasts. J Cell Biochem. 29:127–141.
1985.
|
|
11
|
Schmitt JM and Stork PJ: Cyclic
AMP-mediated inhibition of cell growth requires the small G protein
Rap1. Mol Cell Biol. 21:3671–3683. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xia Y, Gong KZ, Xu M, Zhang YY, Guo JH,
Song Y, et al: Regulation of gap-junction protein connexin 43 by
β-adrenergic receptor stimulation in rat cardiomyocytes. Acta
Pharmacol Sin. 30:928–934. 2009.
|
|
13
|
Keller DM, Clark EA and Goodman RH:
Regulation of microRNA-375 by cAMP in pancreatic β-Cells. Mol
Endocrinol. 26:989–999. 2012.PubMed/NCBI
|
|
14
|
Lu Y, Zhang Y, Shan H, Pan Z, Li X, Li B,
et al: MicroRNA-1 downregulation by propranolol in a rat model of
myocardial infarction: a new mechanism for ischaemic
cardioprotection. Cardiovasc Res. 84:434–441. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Toll L, Jimenez L, Waleh N, Jozwiak K, Woo
AY, Xiao RP, et al: Beta2-adrenergic receptor agonists inhibit the
proliferation of 1321N1 astrocytoma cells. J Pharmacol Exp Ther.
336:524–532. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bos JL: Epac proteins: multi-purpose cAMP
targets. Trends Biochem Sci. 31:680–686. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dbouk HA, Mroue RM, El-Sabban ME and
Talhouk RS: Connexins: a myriad of functions extending beyond
assembly of gap junction channels. Cell Commun Signal. 7:42009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Laird D, Puranam K and Revel JP: Turnover
and phosphorylation dynamics of connexin43 gap junction protein in
cultured cardiac myocytes. Biochem J. 273:67–72. 1991.PubMed/NCBI
|
|
19
|
Salameh A and Dhein S: Pharmacology of gap
junctions. New pharmacological targets for treatment of arrhythmia,
seizure and cancer? Biochim Biophys Acta. 1719:36–58. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Duquesnes N, Derangeon M, Métrich M, Lucas
A, Mateo P, Li L, et al: Epac stimulation induces rapid increases
in connexin 43 phosphorylation and function without preconditioning
effect. Pflugers Arch. 460:731–741. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Beese M, Wyss K, Haubitz M and Kirsch T:
Effect of cAMP derivates on assembly and maintenance of tight
junctions in human umbilical vein endothelial cells. BMC Cell Biol.
7:11–68. 2010.PubMed/NCBI
|
|
22
|
Somekawa S, Fukuhara S, Nakaoka Y, Fujita
H, Saito Y and Mochizuki N: Enhanced functional gap junction
neoformation by protein kinase A-dependent and Epac-dependent
signals downstream of cAMP in cardiac myocytes. Circ Res.
97:655–662. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hanstein R, Trotter J, Behl C and Clement
AB: Increased connexin 43 expression as a potential mediator of the
neuroprotective activity of the corticotropin-releasing hormone.
Mol Endocrinol. 23:1479–1493. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Van Rooij E: The art of microRNA research.
Circ Res. 108:219–234. 2011.
|
|
25
|
Wightman B, Ha I and Ruvkun G:
Posttranscriptional regulation of the heterochronic gene lin-14 by
lin-4 mediates temporal pattern formation in C. elegans. Cell.
75:855–862. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nicholas TW, Read SB, Burrows FJ and Kruse
CA: Suicide gene therapy with Herpes simplex virus thymidine kinase
and ganciclovir is enhanced with connexins to improve gap junctions
and bystander effects. Histol Histopathol. 18:495–507.
2003.PubMed/NCBI
|
